Wire · opportunities
RELATIVITY-047's Five-Year Data Just Made LAG-3 Biomarker Selection a Clinical Trial ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
The five-year Phase 3 data from the RELATIVITY-047 trial demonstrates that selecting patients with high LAG-3 expression significantly improves survival outcomes in metastatic melanoma when treated with relatlimab plus nivolumab. This data reveals the strategic need for prospective biomarker-enriched trial designs for next-generation LAG-3 inhibitors, contrasting with prior broad enrollment approaches.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to prioritise biomarker-selected patient enrolment for LAG-3 trials now that regulators favour enriched designs. Your broad population approach will lose competitive and regulatory ground as labels tighten on populations showing clear survival benefits.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics